Scandinavian ChemoTech: Exceptional 97% Remission in Equine Study - Redeye

Scandinavian ChemoTech has announced the early publication of an independent clinical abstract ahead of the ECVS congress (July 9–11). The study reports an outstanding 97% complete remission rate for equine sarcoids treated under standing sedation. While we already anticipated encouraging results and leave our financial model unchanged, this data de-risks the commercial roll-out of the vetIQure™ platform.

Länk till analysen i sin helhet: https://www.redeye.se/research/1173109/scandinavian-chemotech-exceptional-97-remission-in-equine-study?utm_source=finwire&utm_medium=RSS